KPTIQ — Karyopharm Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1503802 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 33,432,000 | 32,347,000 | -22,526,000 | -67,023,000 | 111,317,000 | 54,980,000 | 441,485,000 |
| Mar 2026 | 35,066,000 | 33,721,000 | -26,760,000 | -22,392,000 | 131,417,000 | 90,850,000 | 397,063,000 |
| Dec 2025 | 34,079,000 | 32,595,000 | -17,844,000 | -102,198,000 | 108,416,000 | 60,540,000 | 401,342,000 |
| Sep 2025 | 44,044,000 | 41,931,000 | -15,220,000 | -33,127,000 | 96,232,000 | 37,672,000 | 365,490,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-65,347,000
Investing CF
$2,969,000
Financing CF
$78,596,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.09
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,848,914,000
Inventory
$3,994,000
Receivables
$29,871,000
ST Investments
$10,125,000
EBIT TTM
$-175,448,000
Pretax Income TTM
$-224,772,000
Interest Exp TTM
$49,324,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$146,620,992
EBITDA
$-82,201,000
Free Cash Flow
$-29,674,250
Enterprise Value
$263,821,920
Total Cash
$65,105,000
Total Debt
$328,529,984
Shares Out
—
Trailing EPS
—
Book Value
$-14.56
ROE
—
ROA
-47.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 146,067,000 | -90,707,000 | -196,039,000 | 108,416,000 | 401,342,000 | -292,926,000 | -75,369,000 |
| Dec 2024 | 145,237,000 | -119,443,000 | -76,422,000 | 164,418,000 | 350,435,000 | -186,017,000 | -127,486,000 |
| Dec 2023 | 146,033,000 | -129,540,000 | -143,099,000 | 240,438,000 | 376,644,000 | -136,206,000 | -92,723,000 |
| Dec 2022 | 157,074,000 | -142,202,000 | -165,291,000 | 358,172,000 | 374,828,000 | -16,656,000 | -149,554,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$146,621,000
NetIncome TTM
$-224,740,000
OpCashFlow TTM
—
Assets (Latest)
$111,317,000
Forward EPS
$-1.92
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
Recent Insider Activity
No insider activity indexed for this ticker.